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Introduction and Hypothesis: Single-nucleotide polymorphisms
(SNPs) and haplotypes in the x-ray repair cross-complementing
group 1 (XRCC1) gene, which is one of the base excision repair
genes, are thought to be associated with the risk of non-small cell
lung cancer (NSCLC).
Methods:We genotyped three coding (Arg280His, Arg399Gln, and
Gln632Gln) SNPs and six haplotype-tagging SNPs (htSNPs) for 140
advanced NSCLC cases and 217 healthy controls (all Koreans)
using unconditional logistic regression analysis, and this was ad-
justed for age, gender, and the smoking status. The haplotypes were
reconstructed according to the genotyping data and the linkage
disequilibrium status of these nine SNPs.
Results: The minor allele heterozygotes of the rs1001581 htSNP
showed an increased risk of NSCLC (adjusted odds ratio  2.118,
p  0.013), and the minor allele homozygotes of the rs2293036
htSNP showed a decreased risk of NSCLC (adjusted odds ratio 
0.363, p  0.020). Seven possible haplotypes were demonstrated in
this study (haplotype frequency 1%). The GGGGGGGGG haplo-
type, which is composed of nine major alleles, showed a protective
effect for developing NSCLC (odds ratio  0.433, p  0.002);
however, the GGGGGGAGG haplotype that contained the minor allele
of the rs1001581 demonstrated an increased risk of NSCLC (odds
ratio 1.597, p 0.044). The above associations were similarly noted
for the never smokers, and so the smoking status might modify the
associations between the x-ray repair cross-complementing group 1
(XRCC1) genetic variants and the risk of developing NSCLC. On
10-million permutation testing, only the GGGGGGGGG haplotype was
significantly associated with a decreased risk of NSCLC in the total
group (p  0.001).
Conclusions: This study presents several novel aspects of the
genetic susceptibility to develop NSCLC. Larger studies that will
focus on the role of the rs1001581 and rs2293036 htSNPs and
haplotypes for developing NSCLC are needed in the future.
Key Words: Lung cancer, XRCC1, Single nucleotide polymor-
phism, Haplotype, Haplotype-tagging SNP.
(J Thorac Oncol. 2010;5: 1912–1921)
Lung cancer is one of the most common cancers worldwide,and non-small cell lung cancer (NSCLC) accounts for 85%
of all the cases of lung cancer.1 Although smoking is considered
a major risk factor for lung cancer, less than 20% of lifetime
smokers develop lung cancer, suggesting that genetic suscepti-
bility plays an important role in lung carcinogenesis.2
The x-ray repair cross-complementing group 1 (XRCC1)
plays a central role in the base excision repair pathway, and
the base excision repair pathway is the primary mechanism
for repairing small base lesions in DNA that are the result of
oxidation and alkylation damage.3,4 Many studies have re-
ported that various single-nucleotide polymorphisms (SNPs)/
haplotypes in the XRCC1 gene may be associated with the
individual susceptibility to smoking-related cancers and es-
pecially lung cancer.5–14 Three coding SNPs, Arg194Trp,
Arg280His, and Arg399Gln, are the most studied SNPs in the
XRCC1 gene. Many studies have shown that these SNPs are
associated with a reduced or increased risk of lung cancer, but
some nonsignificant or negative associations have also been
reported by other studies.8,15–23 Nevertheless, the results have
frequently been inconsistent, and a previously published
meta-analysis shows that when stratified by ethnicity, an
association of the SNPs was present in Asians but not in
whites,24 suggesting that the effect of the XRCC1 SNPs on
lung cancer may be dependent on ethnicity. Moreover, the
results of studies that investigated the effect of the XRCC1
genetic variants on lung cancer from the same population
were also inconsistent.25 Thus, an ethnicity-based, case-con-
trol study of the Korean population is needed.
The previous studies of the XRCC1 gene had focused
on the association between the coding SNPs and the cancer
risk, whereas this study evaluated not only the three coding
SNPs (Arg280His, Arg399Gln, and Gln632Gln) but also six
additional haplotype-tagging SNPs (htSNPs). Our aim was to
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comprehensively study the role of the individual SNP and the
role of each haplotype for the susceptibility to NSCLC in a
case–control study of a Korean population. Furthermore, gene-
smoking analyses were conducted to study the gene-environ-
ment interactions between the studied SNPs and/or haplotypes
and the cigarette smoking status of patients with NSCLC.
PATIENTS AND METHODS
Patients and Specimens
For this case-control study, blood specimens were col-
lected from 140 consecutive patients who were diagnosed
with advanced NSCLC at Gyeongsang National University
Hospital and Dong-A Medical Center between January 2005
and May 2009. As controls, we collected blood samples from
217 healthy volunteers who were without a history of cancer
or other serious illness and who visited the general health
check-up division at Gyeongsang National University Hos-
pital between November 2006 and January 2008. All the
subjects were ethnic Koreans. The blood specimens were
obtained after receiving written informed consent from all the
subjects. The study protocol was approved by the Institu-
tional Review Boards at Gyeongsang National University
Hospital and Dong-A Medical Center. A standardized ques-
tionnaire was carried out to collect data from the study
subjects on age, gender, and the smoking history (Table 1).
The participants were defined as never smokers if they had
not smoked more than 100 cigarettes in their lifetime and ever
smokers if they had.
Selection of the Coding and Haplotype-
Tagging SNPs
We used a two-step approach for selecting the relevant
SNPs to assess the genetic variation in the XRCC1 gene. First,
we chose the commonly studied coding SNPs that have been
identified in the literature and that have indicated to be
associated with the lung cancer risk and with an altered
overall capacity to repair DNA. Rs3547 (Gln632Gln),
rs25487 (Arg399Gln), and rs25489 (Arg280His) were in-
cluded in this study. Second, we added htSNPs with the aim
of ensuring good marker coverage for haplotype reconstruc-
tion26 and to increase the analytic efficiency. These additional
SNPs were chosen from public databases called the Inter-
national HapMap Project Phase II data (available at:
http://www.ncbi.nih.gov/; http://www.hapmap.org/).27 Using
the algorithm-Tagger-pairwise method in the International
HapMap Project Phase II data, only the htSNPs with a minor
allele frequency more than 10% were considered, and the
threshold of pairwise linkage disequilibrium (LD) was set as
a squared correlation coefficient (r2) more than 0.8. Ten and
seven htSNPs were picked out from the population of Han
Chinese and Japanese, respectively. Among the picked
htSNPs, six SNPs were observed in both the Han Chinese and
Japanese. We selected eight htSNPs in the XRCC1 gene for
optimization and initial genotyping in 90 samples from the
controls. Two htSNPs were excluded: one was found to be
monomorphic in our specimen and one assay did not show
robust results (success rate  95%). After removing the two
htSNPs that did not meet our quality criteria, nine SNPs
(three coding SNPs and six intronic htSNPs in the XRCC1
gene, Table 2) were genotyped in the study subjects.
Genotyping Methods
The DNA samples were genotyped using matrix-as-
sisted laser desorption/ionization time of flight mass spec-
trometry (Sequenom Inc., San Diego, CA).28 Polymerase
chain reaction (PCR) assays and associated extension reac-
tions were designed using the SpectroDESIGNER software
(Sequenom), and the primers were obtained from BiONEER
(BiONEER, Daejeon, Korea). All the amplification reactions
were run under the same conditions in a total volume of 5 l
with 2.5 ng of genomic DNA, 1 pmol of each amplification
primer, 0.2 mmol/liter of each deoxynucleotide triphosphate,
2.5 mmol/liter MgCl2, and 0.2 units of HotStart DNA poly-
merase (BiONEER). The reactions were heated at 95°C for
15 minutes, and then 45 cycles of amplification (20 seconds
at 94°C, 30 seconds at 60°C, and 30 seconds at 72°C) were
done before a final extension step of 7 minutes at 72°C. The
extension reactions were conducted in a total volume of 9 l
using 5 pmol of the allele-specific extension primer and the
Mass EXTEND Reagents Kit before being cleaned using
SpectroCLEANER (Sequenom) on a MULTIMEK 96 auto-
mated 96-channel robot (Beckman Coulter, Fullerton, CA).
TABLE 1. Baseline Characteristics of This Study Population
Cases (n  140) Controls (n  217) pa
Age (mean  SD) 61.2  9.3 46.4  11.3 0.001
Age group, n (%)
40 3 (2.1) 63 (29.0) 0.001
40–49 11 (7.86) 66 (30.4)
50–59 43 (30.7) 63 (29.0)
60–69 53 (37.9) 19 (8.8)
70 30 (21.4) 6 (2.8)
Gender, n (%)
Male 103 (73.6) 126 (58.1) 0.003
Female 37 (26.4) 91 (41.9)
Cigarette smoking
status, n (%)
bNever smokers 54 (38.6) 133 (61.3) 0.001
bEver smokers 86 (61.4) 84 (38.7)
Histology
Squamous cell
carcinoma
85 (60.7)
Adenocarcinoma 51 (36.4)
Large cell
carcinoma
3 (2.1)
Bronchoalveolar
cell carcinoma
1 (0.7)
TNM stage
Stage IIIA 9 (6.4)
Stage IIIB 44 (31.4)
Stage IV 87 (62.1)
a Two sided 2 tests were applied for the age group, gender, and smoking status,
and independent t tests were applied for age.
b Participants were defined as never smokers if they had not smoked more than 100
cigarettes in their lifetime and ever smokers otherwise.
TNM, tumor, node, metastasis.
Journal of Thoracic Oncology • Volume 5, Number 12, December 2010 The XRCC1 Polymorphisms and Haplotypes and NSCLC
Copyright © 2010 by the International Association for the Study of Lung Cancer 1913
The clean primer extension products were loaded onto a
384-element chip with a nanoliter pipetting system (Spectro-
CHIP, SpectroJet, Sequenom), and they were analyzed by a
MassARRAY mass spectrometer (Bruker Daltonik GmbH,
Bremen, Germany). The resulting mass spectra were ana-
lyzed for peak identification using the SpectroTYPER RT 2.0
software (Sequenom). For each SNP, two independent scor-
ers confirmed all the genotypes. We used 12 quality control
samples for every 384-well plate assay, and none of these
failed. In addition, regenotyping of 5% of the study samples
resulted in more than 99% concordance. Hardy-Weinberg cal-
culations were done to ensure that each marker was within
allelic population equilibrium in our control sample set,29 and
the success rate of each assay was more than 95%.
LD and Haplotype Analyses
Pairwise measures of LD as measured by the Lewontin
coefficient (D; D  D/Dmax) and r
2 between the SNPs that
were genotyped were calculated with the Haploview version
4.1 software program (Broad Institute of MIT and Harvard,
Cambridge, MA).30 The haplotype frequency estimation and
association analyses were performed using the Haploview
program. The haplotypes with a frequency of less than 0.01
were not considered in the analysis.
Statistical Analyses
We determined whether the allelic distribution of the nine
SNPs was consistent with Hardy-Weinberg equilibrium using
the 2 test. The allele and genotype frequencies of these SNPs
were compared between the cases and controls using the 2 test
or Fisher’s exact test. Unconditional logistic regression was
done to estimate the odds ratios (ORs) and 95% confidence
intervals (CIs) of the individual SNPs or haplotypes. The logistic
regression model included adjustment for the variables of the
study: age (in 10-year intervals), gender, and the smoking status.
We investigated the possible interactions between the smoking
status and the SNP genotypes and haplotypes. Because the
haplotype analyses use more degrees of freedom than single-
locus analyses and adjustment of additional covariates also
decreases the statistical power, we did haplotype analyses with-
out accounting for the variables of the study. We also did tests
of the main effects of a single loci or haplotype with adjustment
for multiple testing based on the permutation step-down proce-
dure using the Haploview program. On the permutation testing,
the frequencies of single markers and haplotypes in this block
were compared (i.e., “the Single Markers and Haplotypes in
Blocks” option was used). Ten million permutations were per-
formed. The p values reported in the study were based on
two-sided probability tests with statistical significance set at p
value less than 0.05. The statistical data were obtained using the
SPSS software package version 11.5 (SPSS, Chicago, IL).
RESULTS
Characteristic of the Study Group and an
Overview of the Selected SNPs
As shown in Table 1, there were a higher proportion of
men, an older age, and smokers among the patients with
NSCLC than among the controls (p  0.001, p  0.001, and
p 0.001, respectively). Table 2 provided an overview of the
SNPs selected for analyses, including the reference SNP ID,
the change of amino acid (if available), the chromosome
position, the contig position, and the minor allelic frequencies
among the control subjects of the study. The allele frequen-
cies of these SNPs in the controls were in Hardy-Weinberg
equilibrium. No significant difference in the allele frequen-
cies at any of these nine polymorphic sites was observed
between the NSCLC cases and the controls in this study.
Associations between the XRCC1 SNPs and the
Risk of NSCLC
The adjusted ORs (AORs) of NSCLC in relationship to
the studied single-locus genotypes are presented in Table 3.
When examining the nine SNPs in the XRCC1 gene as
adjusted for age at the time of diagnosis (cases) or enrollment
(controls), (40, 40–49, 50–59, 60–69, and 70 years),
gender, and the smoking status, the minor allele heterozygotes of
the rs1001581 htSNP increased the risk of NSCLC (AOR 
2.118, 95% CI: 1.175–3.818, p  0.013), and the minor allele
homozygotes of the rs2293036 htSNP decreased the risk of
NSCLC (AOR  0.363, 95% CI: 0.254–0.854, p  0.020).
TABLE 2. List of the Information of the Selected SNPs and the Minor Allele Frequencies of the XRCC1 Gene among the
Study Controls
Reference
SNP ID
Amino Acid
Change
Chromosome
Position
Contig
Position
Observed
Heterozygocity
Predicted
Heterozygocity pa
Major
Allele
Minor
Allele
Minor Allelic
Frequency
rs3547 Gln632Gln 48,739,390 16,315,768 0.167 0.153 0.404 G A 0.084
rs25487 Gln399Arg 48,747,566 16,323,944 0.286 0.306 0.410 G A 0.189
rs25486 — 48,747,738 16,324,116 0.315 0.324 0.777 G A 0.204
rs25489 His280Arg 48,748,252 16,324,630 0.154 0.150 1.000 G A 0.082
rs2293036 — 48,749,888 16,326,266 0.442 0.477 0.343 G T 0.392
rs1799778 — 48,750,981 16,327,359 0.284 0.306 0.379 G A 0.188
rs1001581 — 48,757,228 16,333,606 0.361 0.413 0.087 G A 0.292
rs12611088 — 48,764,642 16,341,020 0.263 0.304 0.080 G A 0.187
rs3213282 — 48,764,720 16,341,098 0.290 0.292 1.000 G C 0.177
a The allele frequencies of these nine SNPs were in Hardy-Weinberg equilibrium in the controls.
XRCC1, x-ray repair cross-complementing group 1; SNP, single-nucleotide polymorphism.
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Associations between the XRCC1 SNPs and the
Risk of NSCLC According to the Smoking
Status
We demonstrated the evidence of effect modification by
cigarette smoking (ever smokers versus never smokers) on the
analyses of the XRCC1 single-loci genotypes in Table 4. The
AOR of the smoking status was 3.073 (95% CI: 1.429–6.611,
p 0.004) using unconditional logistic regression analysis with
adjustment for age at the time of enrollment (40, 40–49,
50–59, 60–69, and70 years), the moderately significant SNPs
with p  0.20 (rs25487, rs25486, rs25489, rs2293036,
rs1799778, rs1001581, rs12611088, and rs3213282), and gen-
der. The genetic influences were not observed among the ever
smokers. In contrast, the subjects with the minor allele heterozy-
gotes and minor allele homozygotes of the rs1001581 htSNP
were at an increased risk of NSCLC compared with the subjects
with the homozygotes of the major allele (AOR  4.302, 95%
CI: 1.809–10.230, p  0.001; AOR  3.481, 95% CI: 1.199–
2.536, p 0.022, respectively), and the subjects with the minor
allele homozygote of the rs2293036 htSNP had a decreased risk
of NSCLC (AOR, 0.066, 95% CI: 0.008–0.579, p  0.014)
among the never smokers.
TABLE 3. Genotype Frequencies of the XRCC1 SNPs among the NSCLC Cases and Controls and Their
Associations with the Risk of NSCLC
Genotype
Cases,
n  140,
n (%)
Control,
n  217,
n (%) Adjusted pa
Adjusted
OR (95% CI)
rs3547 (Gln632Gln, c.1896GA) p for trend  0.742 1.127 (0.554–2.292)
GG 116 (82.6) 179 (83.3) 1.00 (Reference)
GA 24 (17.1) 36 (16.7) 0.742 1.127 (0.554–2.292)
AA 0 (0) 0 (0) Not defined
rs25487 (Gln399Arg, c.1196GA) p for trend  0.145 1.402 (0.890–2.209)
GG 81 (58.3) 145 (66.8) 1.00 (Reference)
GA 51 (36.7) 62 (28.6) 0.127 1.579 (0.878–2.840)
AA 7 (5.0) 10 (4.6) 0.489 1.529 (0.459–5.087)
rs25486 (c.1083–59GA) p for trend  0.070 1.520 (0.966–2.392)
GG 75 (54.0) 138 (63.9) 1.00 (Reference)
GA 57 (41.0) 68 (31.5) 0.050 1.542 (0.983–2.420)
AA 7 (5.0) 10 (4.6) 0.431 1.626 (0.486–5.442)
rs25489 (His280Arg, c.839GA) p for trend  0.064 1.854 (0.965–3.564)
GG 107 (76.4) 180 (84.1) 1.00 (Reference)
GA 33 (23.6) 33 (15.4) 0.113 1.759 (0.874–3.538)
AA 3 (2.1) 1 (0.5) 0.299 7.212 (0.174–299.053)
rs2293036 (c.415–213GA) p for trend  0.022 0.631 (0.425–0.936)
GG 64 (45.7) 84 (38.7) 1.00 (Reference)
GA 61 (43.6) 96 (44.2) 0.254 0.714 (0.400–1.274)
AA 15 (10.7) 37 (17.1) 0.020 0.363 (0.254–0.854)
rs1799778 (c.256–185GT) p for trend  0.149 1.398 (0.887–2.206)
GG 80 (58.0) 144 (67.0) 1.00 (Reference)
GT 51 (37.0) 61 (28.4) 0.130 1.577 (0.874–2.846)
TT 7 (5.1) 10 (4.7) 0.494 1.521 (0.457–5.057)
rs1001581 (c.145–216 GA) p for trend  0.034 1.516 (1.031–2.2292)
GG 52 (37.1) 114 (52.8) 1.00 (Reference)
GA 66 (47.1) 78 (36.1) 0.013 2.118 (1.175–3.818)
AA 22 (15.7) 24 (11.1) 0.153 1.828 (0.0799–4.183)
rs12611088 (c.1446260GA) p for trend  0.257 1.288 (0.832–1.995)
GG 83 (59.3) 148 (68.2) 1.00 (Reference)
GA 49 (35.0) 57 (26.3) 0.137 1.569 (0.866–2.844)
AA 8 (5.7) 12 (5.5) 0.752 1.195 (0.395–3.6121)
rs3213282 (c.1446182GC) p for trend  0.196 1.370 (0.850–2.209)
GG 86 (61.4) 147 (67.7) 1.00 (Reference)
CG 47 (33.6) 63 (29.0) 0.250 1.408 (0.786–2.520)
CC 7 (5.0) 7 (3.2) 0.446 1.726 (0.423–7.039)
a Adjusted p value, adjusted ORs, and 95% CIs were estimated using unconditional logistic regression analysis and adjusted for age at the time of
enrollment (40, 40–49, 50–59, 60–69, and 70 yr), gender, and the smoking status.
XRCC1, x-ray repair cross-complementing group 1; SNP, single-nucleotide polymorphism; NSCLC, non-small cell lung cancer; OR, odds ratio; CI,
confidence interval.
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Association between the XRCC1 Haplotypes
and the Risk of NSCLC
The D value and r2 for the studied nine SNPs were
calculated with the Haploview program 4.1, and these are
shown in Figure 1. Their LD maps measured by D in the
total group and the never-smokers group are also shown in
Figure 1. All these selected SNPs were in strong LD among
the total group and the never smokers (D  0.8). The
estimated haplotype frequencies of the XRCC1 SNPs in the
patients with NSCLC and controls among the total group,
ever smokers, and never smokers group are shown in Table
5. Seven possible haplotypes were demonstrated (haplo-
type frequency  1%). Among the total group that in-
cluded the ever smokers and never smokers, a haplotype
GGGGGGGGG, which contained the major alleles of the
nine SNPs, showed a protective effect against NSCLC
(OR  0.433, 95% CI: 0.246–0.740, p  0.002), and the
associations are described in Table 5. The GGGGGGAGG
haplotype containing the rs1001581 minor alleles was
associated with an increased risk of NSCLC (OR  1.597,
95% CI: 1.009–2.528, p  0.044), and the GGGAGGGGC
haplotype containing the rs25486 and rs3213282 minor
alleles was associated with a decreased risk of NSCLC
(OR  1.732, 95% CI: 1.049–2.859, p  0.028). Similar
associations were noted among the never smokers. The
GGGGGGGGG haplotype and the GGGGAGGGG haplo-
type containing the rs2293036 minor allele showed an
inverse association with NSCLC (OR  0.320, 95% CI:
0.122–0.841, p  0.016; OR  0.572, 95% CI: 0.348–
0.939, p  0.026, respectively), and the associations are
described in Table 5. The GGGGGGAGG haplotype was
associated with an increased risk of NSCLC (OR  2.012,
95% CI: 1.074–3.769, p  0.027). No association between
any haplotype and the risk of NSCLC was observed for the
ever smokers. On 10-million permutation testing, only the
GGGGGGGGG haplotype among the significant haplo-
types was significantly associated with a decreased risk of
NSCLC in the total group (p  0.001).
DISCUSSION
This study showed the association of nine SNPs (three
coding SNPs: Arg280His, Arg399Gln, and Gln632Gln and
FIGURE 1. Linkage disequilibrium (LD) maps of the nine single-nucleotide polymorphisms (SNPs) in the non-small cell lung
cancer cases and controls in the total group and the never smokers group. The values of pairwise D (upper figures) and r2 (lower
figures) between the pairs of adjacent markers were calculated with the Haploview software. The value in each diamond is the mea-
sured D corresponding to the dark gray-to-white color gradient. Diamonds without a number indicate that the value of D was 1.
Both groups showed strong LD with each SNP (D  0.8). No white color diamond is noted.
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six intronic htSNPs: rs25486, rs2293036, rs1799778,
rs1001581, rs12611088, and rs3213282) and haplotypes in
the XRCC1 gene with the risk for NSCLC in a Korean
population. Because these SNPs may alter the DNA repair
capacity and subsequently lead to synergistic effects with
NSCLC induced by cigarette carcinogens, their relationship
with the smoking status in NSCLC was also examined.
Furthermore, recent studies have suggest that, compared with
the single SNP approaches for genetic association studies,
analyses based on haplotypes can significantly improve the
power for detecting associations and increase robustness
between markers and disease.31
Analyses of the data showed that the strongest associ-
ation with the increased NSCLC risk was found for the
rs1001581 heterozygotes (AOR  2.118, p  0.013). The
increased lung cancer risk associated with this SNP was
mainly attributable to the never smokers (AOR  4.302, p 
0.001 for the minor allele heterozygotes and AOR  3.481,
p  0.022 for the minor allele homozygotes). We found a
significantly decreased risk for NSCLC for the individuals
with the minor allele homozygotes for the rs2293036 htSNP
(AOR  0.363, p  0.020). The decreased NSCLC risk
associated with rs2293036 polymorphism was also attribut-
able to never smokers (AOR  0.066, p  0.014). Our data
indicated that genetic variations in the XRCC1 gene may be
of relevance to the risk of NSCLC and perhaps mainly for the
never smokers. Associations with the NSCLC risk were
observed for two specific SNPs, and these rs1001581 and
rs2293036 htSNPs are located in areas with unknown func-
tional significance. No significant relationships with the over-
all NSCLC risk have been reported for these htSNPs in white,
Japanese, and Chinese populations with the exception being
Latinos. The minor allele, A allele at the rs1001581 htSNP
(c.145-216GA, previously called IVS2-216GA) was sig-
nificantly associated with NSCLC in Latinos (AOR  1.53,
95% CI: 1.04–2.26, p  0.03).17 Furthermore, the A allele at
the rs1001581 htSNP was inversely associated with the risk
of colorectal adenoma in whites (p trend  0.003).32 Never-
theless, it remains unclear whether any true association is due
to the identified markers or to other unidentified genetic
susceptibility loci belonging to the haplotype. We did not
have much data on the rs1001581 and rs2293036 htSNPs and
the risk of NSCLC; these significant genetic variants in our
study were intronic htSNPs. Thus, if the associations of the
XRCC1 gene are replicated, then fine mapping and further
investigation would be required to identify the causal variant(s).
TABLE 5. Frequencies of the Haplotypes of the XRCC1 Gene in the NSCLC Cases and Controls and the Associations with the
Risk of NSCLC
Group According to the
Smoking Statusa Haplotypeb Frequency
Case
Proportion
Control
Proportion p OR (95% CI)
Permutated
pc (n  10,000,000)
Total group
GGGGAGGGG 0.361 0.325 0.385 0.103 0.767 (0.559–1.052) 0.456
GAAGGTAAG 0.191 0.221 0.173 0.109 1.358 (0.932–1.978) 0.491
GGGGGGAGG 0.115 0.145 0.096 0.044 1.597 (1.009–2.528) 0.149
GGGGGGGGG 0.109 0.065 0.138 0.002 0.433 (0.246–0.740) 0.001
GGGAGGGGC 0.095 0.125 0.076 0.028 1.732 (1.049–2.859) 0.108
AGGGGGGGC 0.082 0.079 0.084 0.806 0.913 (0.526–1.583) 1.000
GGAGGGAGG 0.013 0.015 0.012 0.685 1.241 (0.330–4.660) 1.000
Ever-smokers group
GGGGAGGGG 0.381 0.365 0.397 0.552 0.874 (0.563–1.357) 1.000
GAAGGTAAG 0.168 0.185 0.150 0.384 1.286 (0.734–2.284) 0.975
GGGGGGGGG 0.110 0.120 0.093 0.083 1.328 (0.662–2.664) 0.259
GGGGGGAGG 0.105 0.077 0.142 0.502 0.502 (0.246–1.021) 1.000
AGGGGGGGC 0.096 0.122 0.054 0.727 2.426 (1.077–5.466) 1.000
GGGAGGGGC 0.092 0.087 0.096 0.074 0.902 (0.430–1.891) 0.234
GGAGGGAGG 0.014 0.019 0.012 0.754 1.604 (0.273–9.412) 1.000
Never-smokers group
GGGGAGGGG 0.345 0.259 0.38 0.026 0.572 (0.348–0.939) 0.205
GAAGGTAAG 0.214 0.278 0.188 0.054 1.666 (0.989–2.806) 0.421
GGGGGGAGG 0.126 0.185 0.102 0.027 2.012 (1.074–3.769) 0.215
GGGGGGGGG 0.107 0.046 0.132 0.016 0.320 (0.122–0.841) 0.120
GGGAGGGGC 0.096 0.13 0.083 0.163 1.652 (0.811–3.363) 0.899
AGGGGGGGC 0.072 0.065 0.075 0.725 0.852 (0.350–2.079) 1.000
GAAGGTGGC 0.011 0.009 0.012 0.838 0.793 (0.082–7.635) 1.000
Rare haplotypes with frequencies of 1% were not shown.
a Participants were defined as never smokers if they had not smoked more than 100 cigarettes in their lifetime and ever smokers otherwise.
b Nine SNPs alleles from left to right (rs3547 Gln632Gln, rs25487 Gln399Arg, rs25486, rs25489 His280Arg, rs2293036, rs1799778, rs1001581, rs12611088, and rs3213282)
were used for reconstruction of the haplotypes.
c Calculated with the Haploview program 4.1.
XRCC1, x-ray repair cross-complementing group 1; SNP, single-nucleotide polymorphism; NSCLC, non-small cell lung cancer; OR, odds ratio; CI, confidence interval.
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The Arg280His and Arg399Gln SNPs have been fre-
quently examined in the previous studies on cancer suscep-
tibility. Especially, the Arg399Gln SNP was the most com-
mon sequence variant among the XRCC1 SNPs. We also
investigated the frequently examined SNPs, Arg280His,
Arg399Gln, and Gln632Gln, but our study did not provide
any valuable associations with the overall lung cancer risk.
On the basis of 6120 lung cancer cases and 6895 controls
from 13 studies, Hung et al.33 did not observe an association
between the Arg399Gln allele and the lung cancer risk in
Asians and whites. After the study by Hung et al., Kiyohara
et al.24 conducted a meta-analysis of the association between
the lung cancer risk and these polymorphisms in the XRCC1
gene. Similarly, study by Kiyohara et al. showed that the
Gln/Gln genotype was significantly associated with an in-
creased risk of lung cancer among Asians but not among
whites. A Chinese meta-analysis by Yin et al.34 found no
associations for the Arg399Gln SNP. From another meta-
analysis of a Chinese populations from eight studies, Zheng
et al.25 showed little evidence of an association between the
combined variant Arg/Gln and the Gln/Gln genotypes of the
XRCC1 Arg399Gln polymorphism and the increased risk of
lung cancer (OR  1.16, 95% CI: 1.00–1.36, p  0.06). Our
results are also consistent with those of the studies by Hung
et al.,33 Yin et al.,34 and Zheng et al.25 In contrast, a study
among an Indian population reported an inverse association
between lung cancer and the Gln allele.21 These inconsisten-
cies between racial groups may be due to the difference in
environmental exposures (e.g., the prevalence and the dose of
cigarette smoking). Alternatively, Arg399Gln may be a proxy
SNP linked to a true causal SNP, and the linkage patterns
may differ across various ancestral groups. Although the
association between Arg399Gln and lung cancer requires
further confirmation, several studies suggest that this poly-
morphism may have a functional impact. Hung et al.33 also
did not find evidence of an association between the risk of
lung cancer and the Arg280His allele based on 2503 lung
cancer cases and 2603 controls from three studies.
We performed haplotype analyses to comprehensively
identify the various genetic variants of the XRCC1 gene in the
Korean population. We found a significantly decreased risk
for NSCLC for the individuals with the haplotype composed
of nine common alleles, GGGGGGGGG (OR  0.433, p 
0.002), and an increased risk of NSCLC for the individuals
with the other haplotype containing the rs1001581 minor
allele, GGGGGGAGG (OR  1.597, p  0.044). These
relationships were also attributable to the never smokers
(GGGGGGGGG haplotype: OR  0.032, p  0.016 and the
GGGGGGAGG haplotype: OR  2.012, p  0.027, respec-
tively). The major difference between the two haplotypes was
the presence or absence of the minor allele of rs1001581.
Among the never smokers, the GGGGAGGGG haplotype,
which encompassed the minor allele(s) of the rs2293036
htSNP, showed a decreased risk of NSCLC (OR  0.572,
p  0.026). The rs2293036 htSNP also demonstrated a
decreased risk of NSCLC (Tables 3 and 4). These findings
indicated that the rs1001581 and rs2293036 htSNPs, or the
closely linked genetic variants, are the biologically effective
genetic variants (Tables 3 and 4). The nine studied SNPs in
the XRCC1 gene were in strong LD (Figure 1). The present
haplotype analysis suggested that this genetic region of the
XRCC1 gene may have a role in modulating lung cancer
susceptibility. Up to now, no significant links with the overall
lung cancer risk have been reported for these haplotypes in
white, Japanese, and Chinese populations. These finding
warrant additional functional studies and validation studies
that will include a large series of NSCLC cases and matched
controls from various ethnic groups.
Although detailed smoking history and other environ-
mental exposure were not investigated in this study, the
statistically significant association between the XRCC1 gene
and smoking was present for the never smokers, and it was
absent for the ever smokers. The exact biologic mechanisms
of the gene-smoking interaction have remained unclear. One
hypothesis is that polymorphic variants of the XRCC1 gene
have different efficiencies in repairing smoking-associated
DNA damage in the never smokers, whereas the DNA dam-
age in ever smokers is so extensive that the differences in
DNA repair efficiencies by these polymorphisms may not be
so manifest. Never smokers with NSCLC are more likely to
have the following characteristics: female gender, adenocar-
cinoma histology, younger age, and improved survival.35
Never smokers with NSCLC in this study had the following
features: female gender, adenocarcinoma, and younger age
(data were not shown). Therefore, XRCC1 genetic study
might have more advantages in the setting of females, never
smokers, and young people. Platinum-based regimens such as
cisplatin or carboplatin are used as standard first-line chemo-
therapy in advanced NSCLC. Although genetic polymor-
phisms in the DNA repair gene XRCC1 and their relation-
ships with phenotypic activity have not yet been thoroughly
identified, several studies have been demonstrated that ge-
netic polymorphisms in the XRCC1 are associated with the
clinical outcome and chemotherapy-related toxicity in pa-
tients with advanced NSCLC treated with platinum-based
chemotherapy.36–38 The identification of the molecular mech-
anisms that confer sensitivity to these chemotherapeutic
agents to avoid toxicity among each individual patient is
appealing. Individualized treatment regimen may eventually
be based on genetic profiling in the future to ensure prolonged
survival and better quality of life among patients with cancer.
A better understanding of the roles of DNA repair genes will
provide further information on the prognostic or predictive
biomarker and treatment-related toxicity.
This study provided some of the first data to support an
association of the genetic variation in the XRCC1 htSNPs and
haplotypes with the risk of NSCLC. Our study has several
limitations. First, because this was a hospital-based, case-
control study, the control group in this study may not have
provided a good representation of the general population.
Nevertheless, because the variant genotype frequencies we
observed in the control population of our study did not differ
significantly from the frequencies predicted by the Hardy-
Weinberg equilibrium theory, it is likely that our study
population accurately represented the general population.
Second, because the cases and controls were enrolled con-
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secutively without matching the variables, age, gender, and
smoking status, the frequency matching the variables were
obviously failed in our analyses. An inadequacy in matching
on age, gender, and smoking status would be controlled in
data analysis with an additional adjustment. Third, patients
with advanced NSCLC were enrolled in this study, the
findings of this study are able to be generalized to an ad-
vanced stage population of cases. Nevertheless, Korea has a
rather high incidence of advanced lung cancer.39,40 As four
fifths of the clinical stage of NSCLC at diagnosis were stage
III or IV, its limitation and influence would be lessened.
Furthermore, polymorphisms as either prognostic or predic-
tive biomarkers have many advantages, especially in ad-
vanced cancer settings. Fourth, detailed smoking histories
and environmental tobacco smoke exposure including envi-
ronmental exposure were relatively incomplete, because the
controls were classified as ever smokers and never smokers.
Given the significant interactions between the XRCC1 geno-
types, smoking status, and the risk of developing lung cancer,
a potential confounding factor may exist. Fifth, because of the
relatively small patient population analyzed, our findings
should be interpreted with caution and require further vali-
dation in subsequent studies. Although our sample size was
small for a genetic study and our sample was not matched for
age, gender, and the smoking status, the study had reasonable
power to detect the main effects for major alleles in the
setting of evaluating hypotheses that have relatively high
previously determined probabilities for the association of
NSCLC with the XRCC1 gene. Furthermore, the most signif-
icant haplotype from the XRCC1 gene remained noteworthy
after the permutation test, and the significant SNPs remained
significant after adjusting for age, gender, and the smoking
status. Nevertheless, our data should be interpreted with
caution, and it should also be viewed as an initial step in
evaluating the role of genetic variation in the XRCC1 gene for
the risk of NSCLC.
CONCLUSIONS
Although the present case–control study has a rela-
tively small sample size, the results clearly show that the
rs1001581 and rs2293036 htSNPs and some haplotypes of the
XRCC1 gene may contribute to the genetic susceptibility for
NSCLC. Furthermore, the smoking status seems to play an
important role in the association between the XRCC1 poly-
morphisms and haplotypes and the risk of NSCLC. Addi-
tional studies are needed to detect the function of these
polymorphisms and their associations with exposure to cig-
arette smoke. On the other hand, the major coding SNPs, i.e.,
Arg280His and Arg399Gln polymorphism, of the XRCC1
gene seemed not to be involved in the risk for NSCLC among
Koreans. Because genetic polymorphisms often significantly
vary between different groups, large-scale studies are needed
to clarify the associations of the single polymorphisms, gene–
gene interactions, and gene–environment interactions with
NSCLC in well-defined ethnic groups.
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